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Abstract Herein, we described a ligand-free copper catalyzed aerobic oxidative 
functionalization of 3,4-dihydroquinoxalin-2-ones with terminal alkynes using 
visible-light and oxygen as terminal oxidant. The corresponding products are 
obtained with moderate to good yields. Moreover, we demonstrate the 
versatility of the propargylic 3,4-dihydroquinoxalin-2-ones obtained, preparing 
several 3,4-dihydroquinoxalin-2-one derivatives.  
Key words dihydroquinoxalinones, alkynes, copper, cross-dehydrogenative 
coupling, oxidation, nitrogen heterocycles 
 
The creation of carbon-carbon (C-C) bonds is a fundamental 
transformation in organic synthesis, therefore the development 
of methodologies for C-C bond formation plays a central role in 
organic chemistry. In this context, the construction of C-C bonds 
through cross-dehydrogenative coupling (CDC) of two accessible 
C-H bonds, under oxidative conditions, has emerged as one of the 
most straightforward approach for increasing molecular 
complexity from an economical point of view with the minimal 
waste generation.1 In this regard, the oxidative dehydrogenative 
sp3-C-H functionalization of tertiary amines have become a hot 
topic in organic synthesis in the last years.2 From all CDC of 
tertiary amines, the oxidative alkynylation represents a powerful 
transformation because this methodology affords propargylic 
amines,3 which are versatile building blocks for the synthesis of 
fine chemicals, pharmaceuticals, agrochemicals or natural 
products.4 Several copper catalyzed oxidative alkynylation of 
amines have been described in the literature using acyclic5 and 
cyclic6 tertiary amines. For example, Li described the 
alkynylation of N,N-dimethylanilines5a as well as N-aril 
tetrahydroisoquinolines6a-b using CuBr as catalyst and 
stoichiometric tBuOOH as oxidant. Fu5b described the copper 
catalyzed alkynylation of acyclic tertiary amines using N-
bromosuccinimide (NBS) as oxidant, while Li5f described the use 
of diethyl azodicarboxylate (DEAD) as oxidant. Concerning cyclic 
amines, Rueping6c and Khan6e described the copper catalyzed 
oxidative alkynylation of N-aril tetrahydroisoquinolines using 
visible-light and O2 as oxidant. However, the corresponding 
oxidative alkynylation of dihydroquinoxalin-2-ones has not been 
described despite the importance of such scaffold in medicinal 




























Scheme 1 Oxidative cross-dehydrogenative coupling of cyclic amines with 
terminal alkynes 
Quinoxaline derivatives are an important class of nitrogen 
heterocyclic compounds present in numerous pharmaceuticals 
and biologically active compounds.7 Consequently, many of them 
serve as key building blocks in synthesis of pharmaceutical 
products. In this context, 3,4-dihydroquinoxalin-2-ones and their 
derivatives display a wide spectrum of biological activities such 
as antiviral,8 antidepressant,9 antitumoral,10 anxiolytic11 among 
others (Figure 1). Therefore, the functionalization of 
dihydroquinoxalin-2-one derivatives is significant for 
pharmaceutical industry. In this context, several oxidative 
functionalization of dihydroquinoxalinones have been described 
recently.12 For example, in 2016 Xiao reported the photocatalytic 
functionalization with benzophenone,12a while Hong, in 2018, 
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reported the Friedel-Crafts alkylation of dihydroquinoxalines 

















































Figure 1 Biologically active 3,4-dihydroquinoxalin-2-one derivatives 
Continuing with our efforts for the synthesis of propargylic 
amines13 and the oxidative sp3-C-H functionalization of amines,14 
in this communication, we report the oxidative alkynylation of 
3,4-dihydroquinoxalin-2-ones with terminal alkynes using 
simple Cu(OTf)2 as catalyst and oxygen as terminal oxidant under 
visible light irradiation.15 
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Entry Cu salt (10 mol%) solvent t (h) 3aa (%)b 
1 CuCl CH3CN 1.5 44 
2 CuI CH3CN 48 - 
3 CuCl2 CH3CN 1.5 27 
4 CuBr2 CH3CN 24 32 
5 Cu(OAc)2·H2O CH3CN 96 21 
6 Cu(OTf)2 CH3CN 20 54 
7 - CH3CN 48 - 
8 Cu(OTf)2 CH3OH 19 33 
9 Cu(OTf)2 toluene 120 50 
10 Cu(OTf)2 CHCl3 216 29 
11 Cu(OTf)2 THF 216 30 
12 Cu(OTf)2 DMF 216 23 
13 Cu(OTf)2 DMSO 216 33 
14c Cu(OTf)2 CH3CN 24 - 
a Reaction conditions: 1a (0.1 mmol), 2a (0.5 mmol), copper salt (10 mol%) in 1mL 
of solvent under open air atmosphere. b Yields after column chromatography. c 
The reaction was runned under Ar atmosphere. 
 
Our investigation was started by examining the model reaction of 
4-benzyl-3,4-dihydroquinoxalin-2(1H)-one 1a with 
phenylacetylene (2a) using copper salts as catalysts under 
visible-light irradiation and open air atmosphere. As shown in 
Table 1, we started the optimization process with the screening 
of several copper salts (10 mol%, entries 1-6) at room 
temperature in CH3CN, obtaining the best yield of the alkynylated 
product 3aa when Cu(OTf)2 was used (54% yield). If the reaction 
was runned in the absence of copper salt, product 3aa was not 
observed (entry 7). Next, different solvents including CH3OH, 
toluene, CHCl3, THF, DMF and DMSO were further screened 
(entries 8-13). The yield of 3aa did not improve in any case 
compared to that obtained when acetonitrile was used as a 
solvent (entry 6). If the reaction was runned under argon 
atmosphere the conversion to product 3aa was very low (entry 
14) indicating that O2 is necessary in the reaction. 
To further improve the efficiency of the oxidative alkynylation 
reaction, several additives were tested (Table 2, entries 1-9). 
From all the additives evaluated, CH3CO2H and SiO2 improved the 
yield of the functionalized dihydroquinoxaline 3aa to 66% and 
68%, respectively. Next, using these additives different sources 
of light were evaluated (11 W white bulb and Blue LEDs, entries 
9-12), observing a slightly decrease on the efficiency of the 
alkynylation reaction. After, the effect of the visible-light was 
evaluated by performing the reaction under darkness (entries 
13-14). The corresponding product 3aa was also obtained, 
however with a diminished yield (48% and 51%). Finally, we 
tried to decrease the equivalents of alkyne to 2.5 (entry 15) and 
reduce the catalyst loading to 5 mol% (entry 16), but the 
dihydroquinoxalinone 3aa was obtained with lower yield. 

















Entry Source of light  Additive (1 eq.) t (h) 3aa (%)b 
1 White LEDs (5W) PhCO2H 48 47 
2 White LEDs (5W) CH3CO2H 26 66 
3 White LEDs (5W) CF3CO2H 3 20 
4 White LEDs (5W) pTsOH 27 24 
5 White LEDs (5W) iPr2NEt 72 - 
6 White LEDs (5W) (PhO)2PO2H 35 44 
7 White LEDs (5W) 3Å MS 29 38 
8 White LEDs (5W) SiO2 27 68 
9 11 W white bulb CH3CO2H 6 59 
10 11 W white bulb SiO2 6 60 
11 Blue LEDs CH3CO2H 6 56 
12 Blue LEDs SiO2 6 60 
13 In the darkness CH3CO2H 25 48 
14 In the darkness SiO2 25 51 
15c White LEDs (5W) SiO2 25 53 
16c,d White LEDs (5W) SiO2 25 22 
a Reaction conditions: 1a (0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 (10 mol%) in 1mL of 
solvent under open air atmosphere. b Yields after column chromatography. c 2.5 
eq. of 2a. d Cu(OTf)2  (5 mol%) 
 
With the optimal conditions established for 3aa (Table 2, entry 
8), the substrate scope of the alkynylation reaction was studied. 
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First, we studied the reaction of several 3,4-dihydroquinoxalin-
2-ones 1 with phenyl acetylene (2a) (Scheme 2). The reaction 
tolerates different protecting groups (Bn, Me, allyl) at the amine 
group of the quinoxalin-2-ones. Nevertheles, when the protecting 
groups are methyl or allyl, the yields are moderate. However, if 
the reaction is run at 50 °C, the yields could be increased. The 
unprotected 3,4-dihydroquinoxalin-2-one 1d, was completely 
oxidized to quinoxalin-2(1H)-one, which did not react with 2a. 
1,4-Dibenzyl-3,4-dihydroquinoxalin-2(1H)-one could be used in 
the alkynylation reaction, and the product 3ea was gained in 54% 
yield when the reaction is performed at 50 °C. Moreover, 4-alkyl-
3,4-dihydroquinoxalin-2-one (1) bearing electron-donating (Me) 
or electron-withdrawing (Cl) groups on the aromatic ring 
furnished the corresponding propargylic cyclic amines 3 in 



































































Scheme 2 Scope of the oxidative alkynylation reaction of 3,4-
dihydroquinoxalin-2-ones 1 with phenylacetylene 2a. a Reaction conditions: 1a 
(0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 (10 mol%) in 1mL of CH3CN under 5W 
White LEDs irradiation and open air atmosphere at rt. b Reaction conditions: 
1a (0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 (10 mol%) in 1mL of CH3CN under open 
air atmosphere at 50 °C without white LEDs irradiation. Yields after column 
chromatography. 
After studying the reaction with different 3,4-dihydroquinoxalin-
2-ones, we focused our attention in the use of various terminal 
alkynes 2 (Scheme 3). First, we explored the reaction with 
several terminal alkynes bearing different electronic and steric 
demands. The presence of an alkyl group (pentyl) in 
the para position resulted in the formation of 3ab with good 
yield (62%). The use of para-fluoro-ethynylbenzene (2c) or para-
chloro-ethynylbenzene (2 d) gave the corresponding 
product 3ac and 3ad with 72% and 61% yield respectively. An 
alkyne bearing a substituent (F) in meta gave 3ae in good yield 
(63%). Finally, in order to fully study the scope of the reaction, 
aliphatic alkynes were evaluated. The reactions were performed 
at 50 °C since this allowed to obtain better conversions.  When 
but-3-yn-1-ylbenzene (2f) or ethynylcyclopropane (2g) were 
used, the corresponding products were obtained with moderate 


































































Scheme 3 Scope of the oxidative alkynylation reaction of 4-benzyl-3,4-
dihydroquinoxalin-2-one 1a with terminal alkynes 2. a Reaction conditions: 1a 
(0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 (10 mol%) in 1mL of CH3CN under 5W 
White LEDs irradiation and open air atmosphere at rt. b Reaction conditions: 
1a (0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 (10 mol%) in 1mL of CH3CN under open 
air atmosphere at 50 °C without white LEDs irradiation. c Dry CH3CN and 
oxygen atmosphere was used. Yields after column chromatography. 
Interestingly, when the reaction is performed with terminal 
alkynes bearing strong electron-donating groups such as 
methoxy group in para or ortho positions or with 2-
ethynylthiophene, the triple bond of product 3 is regioselectively 
hydratated16 under the reaction conditions obtaining the 
corresponding aryl ketone 4 bearing a quinoxalin-2-one moiety 
in moderate to good yields (Scheme 4). We could avoid the 
hydratation product 4 performing the reaction using dry CH3CN 
and oxygen atmosphere. For example, when 1a was reacted with 
ortho-metoxyphenylacetylene under dry conditions  the 
corresponding alkynylated product 3ai was obtained with 44% 









































Scheme 4 S Scope of the oxidative alkynylation reaction of 3,4-
dihydroquinoxalin-2-one 1a with aromatic terminal alkynes bearing electron-
donating groups. a Reaction conditions: 1a (0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 
(10 mol%) in 1mL of CH3CN under 5W White LEDs irradiation and open air 
atmosphere at rt. b Reaction conditions: 1a (0.1 mmol), 2a (0.5 mmol), Cu(OTf)2 
(10 mol%) in 1mL of CH3CN under open air atmosphere at 50 °C without white 
LEDs irradiation. Yields after column chromatography. 
To showcase the synthetic utility of the present methodology, we 
have applied several chemical transformations for the synthesis 
of interesting dihydroquinoxalin-2-one derivatives by selective 
chemical reduction of the C≡C triple bond (Scheme 5). For 
example, the reaction of 3aa with H2 in the presence of Lindlar 
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catalyst gave the corresponding product 5 where the triple bond 
had been reduced stereoselectively to the cis C=C double bond, 
with an excellent 99% yield. On the other hand, a complete 
hydrogenation of the triple bond in the presence of 
Pd/CaCO3(5 %) gave compound 6 with an almost quantitative 
yield. While the reaction of 3aa with Pd/C (5%) under H2 
atmosphere, affords the corresponding dihydroquinoxalin-2-one 
7 in 95% yield, where a complete hydrogenation of the triple 

























5, 99% yield 6, 99% yield
 
Scheme 5 Synthetic transformations of product 3aa. i) Lindlar catalyst (5%), H2, 
benzene. ii) Pd/CaCO3 (5%), H2, EtOH. iii) Pd/C (10%), H2, EtOH. 
Based on previous literature reports5,6 and control experiments17 
a possible mechanism for the reaction is proposed in Scheme 6. 
Initially, Cu(OTf)2 transforms 4-benzyl-3,4-dihydroquinoxalin-
2(1H)-one 1a into a nitrogen radical cation I, with the 
consequent reduction of the Cu(II) to Cu(I), which can be 
oxidized by molecular oxygen (O2) regenerating the copper 
catalyst.17 On the other hand, deprotonation of the nitrogen 
radical cation I can generate the α-amino radical II, which can be 
further oxidized to the iminium ion III. In parallel, the alkyne is 
activated by copper, generating the corresponding copper 
alkynylide.   A further addition of the in situ generated copper 
alkynylide to the iminium ion III gives the desired 
product 3aa and liberates the copper catalyst to complete the 
catalytic cycle. The radical mechanism was confirmed by an 
experiment control using a radical scavenger (TEMPO). Under 
these conditions, no conversion to 3aa was observed by HRMS of 
the crude reaction mixture and the corresponding adduct 8 
formed from radical II and TEMPO was detected. In this 
mechanism, the O2 is the terminal oxidant which is reduced to 
H2O2. The role of molecular oxygen was also studied in a control 
experiment (entry 14, Table 1). When we performed the 
oxidative alkynylation reaction under argon atmosphere, the 
conversion of 1a to product 3aa was very low. We also confirm 
the presence of H2O2 in the reaction mixture.18 Although, the role 
of irradiation is not clear, we think that the visible-light 
accelerates the oxidation of 1a to the iminium ion III (or its 
tautomeric form III’). Regarding obtaining better yields in the 
final alkynylated products 3 when acetic acid or SiO2 are used as 
additives, we assumed that the presence of a weak acid facilitates 
the regeneration of the iminium ion III, if III suffers the 
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Scheme 6 Tentative mechanism for the oxidative alkynylation of 
dihydroquinoxalin-2-ones with terminal alkynes. 
 
In summary, we have developed the oxidative ligand-free 
alkynylation of 3,4-dhydroquinoxalin-2-ones with terminal 
alkynes using Cu(OTf)2 as catalyst under visible-light irradiation 
and open air atmosphere. The reaction conditions are mild, 
obtaining the corresponding products with moderate to good 
yields. Moreover, when electron-rich aromatic alkynes are used 
the regioselective hydratation of the triple bond is observed 
obtaining the corresponding aroyl ketones bearing a quinoxalin-
2-one moiety.  This methodology provides a straightforward 
procedure for the synthesis of a variety of pharmacologically and 
synthetically useful quinoxaline derivatives. 
The experimental section has no title; please leave this line here. 
Reactions were carried out in test tubes or round bottom flasks ovendried 
overnight at 120 °C. Commercial reagents and solvents were used as 
purchased. Reactions were monitored by TLC analysis using Merck Silica 
Gel 60 F-254 thin layer plates. Flash column chromatography was 
performed on Merck silica gel 60, 0.040-0.063 mm. 
NMR spectra were run at 300 MHz for 1H and at 75 MHz for 13C NMR using 
residual non-deuterated solvent as internal standard (CDCl3: 7.26 and 
77.00 ppm respectively; Acetone-d6: 2.05 and 29.84 ppm respectively; 
DMSO-d6: 2.50 and 39.52 ppm respectively) and at 282 MHz for 19F NMR 
using CFCl3 as internal standard. Also, some NMR spectra were run at 400 
MHz for 1H and at 101 for 13C. Chemical shifts are given in ppm. The carbon 
type was determined by DEPT experiments. 
High resolution mass spectra (ESI) were recorded on a AB SCIEX Triple 
TOFTM spectrometer equipped with an electrospray source with a 
capillary voltage of 4.5 kV (ESI). Infrared (IR) spectra were recorded on a 
Agilent Cary 630 FTIR spectrometer.  
All copper salts and terminal alkynes were commercially available 
Dihydroquinoxalinones 1a and 1f was prepared according to a reported 
procedure.12b Dihydroquinoxalinone 1e was prepared following the same 
reported procedure12b but using 2 equivalents of BnBr instead of BnCl. 
Dihydroquinoxalinone 1c was obtained as reported,12b but using allyl 
bromide as alkylating agent instead of BnCl. Dihydroquinoxalinone 1b and 1g 
were synthetized as described in the literature.19 
Procedure A: oxidative alkynylation reaction under white LEDs 
irradiation: 
In a 5 mL vial were placed Cu(OTf)2 (3.6 mg, 10 mol %, 0.01 mmol), SiO2 
(6 mg, 1 eq., 0.1 mmol) and MeCN (1 mL). Then, the proper terminal 
alkyne was added (2, 0.5 mmol, 5 eq.) and the resulting solution was 
stirred for 10 minutes. After this time, the proper dihydroquinoxalinone 
(1, 0.1 mmol) was added and the resulting mixture was stirred under the 
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irradiation of White LEDs (5 W) until the starting material disappeared 
(as showed by TLC).20 Then, the solvent was removed under reduced 
pressure and the residue was purified by FCC to afford product 3. 
Procedure B: oxidative alkynylation reaction at 50 oC: 
In a 10 mL round bottomed flask were placed Cu(OTf)2 (3.6 mg, 10 mol %, 
0.01 mmol), SiO2 (6 mg, 1 eq., 0.1 mmol) and MeCN (1 mL). Then, the 
proper terminal alkyne was added (2, 0.5 mmol, 5 eq.) and the resulting 
solution was stirred for 10 minutes. After this time, the proper 
dihydroquinoxalinone (1, 0.1 mmol) was added and the resulting mixture 
was stirred at 50 oC in an oil bath until the starting material disappeared 
(as showed by TLC). Then, the solvent was removed under reduced 
pressure and the residue was purified by FCC to afford product 3. 
Procedure C: oxidative alkynylation under O2 atmosphere using dry 
MeCN: 
In a 10 mL round bottomed flask were placed Cu(OTf)2 (3.6 mg, 10 mol %, 
0.01 mmol) and SiO2 (6 mg, 1 eq., 0.1 mmol). The flask was purged with 
O2 and afterward dry MeCN (1 m) was added. Then, the proper terminal 
alkyne was added (2, 0.5 mmol, 5 eq.) and the resulting solution was 
stirred for 10 minutes. After this time, the proper dihydroquinoxalinone 
(1, 0.1 mmol) was added and the resulting mixture was stirred under the 
irradiation of White LEDs (5 W) until the starting material disappeared 
(as showed by TLC). Then, the solvent was removed under reduced 
pressure and the residue was purified by FCC to afford product 3. 
4-Benzyl-3-(phenylethynyl)-3,4-dihydroquinoxalin-2(1H)-one 
(3aa) 
Yield: 23.4 mg (68%); yellow solid, m. p.: 174-180 °C. 
IR (neat): 1694, 1655, 1504, 1377, 977, 747, 690 cm-1. 
1H NMR (300 MHz, DMSO) δ 10.81 (bs, 1H), 7.62 – 7.12 (m, 10H), 6.98 – 
6.87 (m, 2H), 6.87 – 6.78 (m, 2H), 4.75 (s, 1H), 4.68 (d, J = 14.6 Hz, 1H), 
4.30 (d, J = 14.5 Hz, 1H). 
13C NMR (75 MHz, DMSO) δ 162.66 (C), 136.80 (C), 133.55 (C), 131.58 
(CH), 129.08 (CH), 128.70 (CH), 128.66 (CH), 128.03 (CH), 127.50 (CH), 
127.44 (C), 123.23 (CH), 121.10 (C), 120.04 (CH), 115.36 (CH), 114.20 
(CH), 85.46 (C), 82.78 (C), 53.81 (CH), 51.59 (CH2). 
HRMS (ESI+): m/z 339.1489 [M + H]+, C23H19N2O requires 339.1492. 
4-Methyl-3-(phenylethynyl)-3,4-dihydroquinoxalin-2(1H)-one 
(3ba) 
Yield: following Procedure A, 10.5 mg (40%), following Procedure B, 12.6 
mg (48%); yellow solid, m. p.: 172-176 °C. 
IR (neat):  1687, 1508, 1388, 744, 684 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.80 (bs, 1H), 7.24 – 7.10 (m, 5H), 7.04 – 6.94 
(m, 1H), 6.79 (dd, J = 4.9, 0.8 Hz, 2H), 6.71 (d, J = 8.0 Hz, 1H), 4.74 (s, 1H), 
2.90 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 163.94 (C), 134.51 (C), 131.95 (CH), 128.62 
(CH), 128.12 (CH), 126.17 (C), 124.39 (CH), 121.85 (C), 120.09 (CH), 
115.52 (CH), 113.41 (CH), 86.84 (C), 80.91 (C), 56.86 (CH), 35.98 (CH3). 
HRMS (ESI+): m/z 263.1180 [M + H]+, C17H15N2O requires 263.1184. 
4-Allyl-3-(phenylethynyl)-3,4-dihydroquinoxalin-2(1H)-one (3ca) 
Yield: following Procedure A, 13.9 mg (48%), following Procedure B, 15.3 
mg (53%); brown oil. 
IR (neat): 1685, 1500, 1217, 923, 751, 686 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.76 (bs, 1H), 7.33 – 7.16 (m, 5H), 7.12 – 6.98 
(m, 1H), 6.93 – 6.82 (m, 3H), 5.96 (dddd, J = 17.5, 10.1, 7.5, 4.9 Hz, 1H), 
5.47 (ddd, J = 17.2, 2.9, 1.5 Hz, 1H), 5.35 (ddd, J = 10.2, 2.6, 1.3 Hz, 1H), 
4.92 (s, 1H), 4.14 (ddd, J = 14.4, 3.4, 1.5 Hz, 1H), 3.75 (dd, J = 14.4, 7.5 Hz, 
1H). 
13C NMR (75 MHz, CDCl3) δ 164.13 (C), 133.91 (C), 132.78 (CH), 131.93 
(CH), 128.59 (CH), 128.12 (CH), 126.44 (C), 124.23 (CH), 121.94 (C), 
120.20 (CH), 119.68 (CH2), 115.74 (CH), 113.94 (CH), 86.50 (C), 81.40 (C), 
53.59 (CH), 50.86 (CH2). 
HRMS (ESI+): m/z 289.1336 [M + H]+, C19H17N2O requires 289.1341. 
1,4-Dibenzyl-3-(phenylethynyl)-3,4-dihydroquinoxalin-2(1H)-one 
(3ea) 
Yield: following Procedure A, 12.8 mg (30%), following Procedure B, 23.1 
mg (54%); yellow solid, m. p.: 110-115 °C. 
IR (neat): 1679, 1502, 1396, 1027, 690 cm-1. 
1H NMR (300 MHz, CDCl3) δ 7.49 – 7.21 (m, 15H), 7.07 – 6.97 (m, 1H), 6.96 
– 6.87 (m, 2H), 6.87 – 6.78 (m, 1H), 5.63 (d, J = 16.3 Hz, 1H), 4.85 (d, J = 
16.4 Hz, 1H), 4.81 (s, 1H), 4.73 (d, J = 13.6 Hz, 1H), 4.20 (d, J = 13.6 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 163.31 (C), 136.41 (C), 135.94 (C), 135.77 (C), 
131.95 (CH), 129.50 (C), 128.93 (CH), 128.82 (CH), 128.66 (CH), 128.60 
(CH), 128.21 (CH), 127.99 (CH), 127.15 (CH), 126.07 (CH), 124.00 (CH), 
121.97 (C), 120.58 (CH), 115.62 (CH), 114.25 (CH), 86.84 (C), 81.52 (C), 
53.84 (CH), 52.33 (CH2), 45.92 (CH2). 
HRMS (ESI+): m/z 429.1665 [M + H]+, C30H25N2O requires 429.1967. 
4-Benzyl-6,7-dimethyl-3-(phenylethynyl)-3,4-dihydroquinoxalin-
2(1H)-one (3fa) 
Yield: following Procedure A, 20.5 mg (56%); yellow oil. 
IR (neat): 1683, 1519, 1396, 1221, 865, 751 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.64 (bs, 1H), 7.45 – 7.26 (m, 8H), 7.25 – 7.18 
(m, 2H), 6.68 (s, 1H), 6.65 (s, 1H), 4.70 (d, J = 13.5 Hz, 1H), 4.64 (s, 1H), 
4.13 (d, J = 13.4 Hz, 1H), 2.20 (s, 3H), 2.17 (s, 3H). 
13C NMR (75 MHz, CDCl3) δ 164.22 (C), 135.93 (C), 132.14 (C), 132.02 
(CH), 131.97 (C), 128.83 (CH), 128.74 (CH), 128.54 (CH), 128.40 (C), 
128.11 (CH), 127.91 (CH), 124.17 (C), 122.09 (C), 116.97 (CH), 115.44 
(CH), 86.52 (C), 81.38 (C), 53.20 (CH), 51.73 (CH2), 19.77 (CH3), 18.82 
(CH3). 
HRMS (ESI+): m/z 367.1813 [M + H]+, C25H23N2O requires 367.1810. 
6,7-dichloro-4-methyl-3-(phenylethynyl)-3,4-dihydroquinoxalin-
2(1H)-one (3ga) 
Yield: following Procedure A, 15.6 mg (47%); yellow solid, m. p.: 
decomposes over 200 °C. 
IR (neat): 1685, 1500, 870, 757 cm-1. 
1H NMR (400 MHz, Acetone-d6) δ 9.89 (bs, 1H), 7.39 – 7.29 (m, 5H), 7.16 
(s, 1H), 7.02 (s, 1H), 4.94 (s, 1H), 3.06 (s, 3H). 
13C NMR (101 MHz, Acetone-d6) δ 163.01 (C), 135.89 (C), 132.61 (CH), 
129.87 (CH), 129.42 (CH), 128.55 (C), 126.58 (C), 122.71 (C), 122.57 (C), 
116.90 (CH), 115.65 (CH), 87.12 (C), 82.21 (C), 56.81 (CH), 36.36 (CH3). 
HRMS (ESI+): m/z 330.0331 [M + H]+, C17H12Cl2N2O requires 330.0327. 
4-Benzyl-3-((4-pentylphenyl)ethynyl)-3,4-dihydroquinoxalin-
2(1H)-one (3ab) 
Yield: following Procedure A, 25.3 mg (62%); yellow oil. 
IR (neat): 2926, 2855, 1687, 1504, 740, 697 cm-1. 
1H NMR (300 MHz, CDCl3) δ 9.17 (bs, 1H), 7.46 – 7.28 (m, 5H), 7.22 (d, J = 
8.2 Hz, 2H), 7.10 – 6.97 (m, 3H), 6.93 – 6.85 (m, 3H), 4.71 (d, J = 13.8 Hz, 
1H), 4.68 (s, 1H), 4.19 (d, J = 13.6 Hz, 1H), 2.61 – 2.50 (m, 2H), 1.62 – 1.48 
(m, 2H), 1.35 – 1.21 (m, 4H), 0.87 (t, J = 6.9 Hz, 3H). 
13C NMR (75 MHz, CDCl3) δ 164.58 (C), 143.86 (C), 135.76 (C), 134.25 (C), 
131.89 (CH), 128.85 (CH), 128.61 (CH), 128.26 (CH), 127.93 (CH), 126.57 
(C), 124.23 (CH), 120.39 (CH), 119.03 (C), 115.83 (CH), 114.01 (CH), 86.92 
(C), 80.39 (C), 53.25 (CH), 51.82 (CH2), 35.79 (CH2), 31.32 (CH2), 30.86 
(CH2), 22.45 (CH2), 13.96 (CH3). 
HRMS (ESI+): m/z 409.2277 [M + H]+, C28H29N2O requires 409.2280. 
4-Benzyl-3-((4-fluorophenyl)ethynyl)-3,4-dihydroquinoxalin-
2(1H)-one (3ac) 
Yield: following Procedure A, 24.6 mg (69%); yellow oil. 
IR (neat): 1669, 1247, 727, 689 cm-1. 
1H NMR (300 MHz, CDCl3) δ 9.38 (bs, 1H), 7.48 – 7.22 (m, 8H), 7.09 – 7.00 
(m, 1H), 7.00 – 6.88 (m, 4H), 4.74 (d, J = 13.8 Hz, 1H), 4.70 (s, 1H), 4.20 (d, 
J = 13.6 Hz, 1H). 
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19F NMR (282 MHz, CDCl3) δ -110.08. 
13C NMR (75 MHz, CDCl3) δ 164.51 (C), 162.65 (d, JC-F = 250.3 Hz, C), 135.65 
(C), 134.13 (C), 133.94 (d, JC-F = 8.4 Hz, CH), 128.89 (CH), 128.56 (CH), 
128.00 (CH), 126.52 (CH), 124.31 (CH), 120.47 (CH), 117.94 (d, JC-F = 3.6 
Hz, C), 115.92 (CH), 115.46 (d, JC-F = 22.1 Hz, CH), 113.99 (CH), 85.63 (C), 
80.93 (d, JC-F = 1.5 Hz, C), 53.17 (CH), 51.86 (CH2). 
HRMS (ESI+): m/z 357.1393 [M + H]+, C23H18FN2O requires 357.1398. 
3-((4-Chlorophenyl)ethynyl)-4-benzyl-3,4-dihydroquinoxalin-
2(1H)-one (3ad) 
Yield: following Procedure A (22.8 mg, 0.061 mmol, 61% yield); following 
Procedure B (25.2 mg, 0.068 mmol, 68% yield); yellow solid, m. p.: 160-
163 °C. 
IR (neat):  1682, 1489, 1504, 822, 742, 699 cm-1. 
1H NMR (300 MHz, CDCl3) δ 9.07 (bs, 1H), 7.45 – 7.31 (m, 5H), 7.21 (s, 4H), 
7.03 (dd, J = 8.1, 4.8 Hz, 1H), 6.97 – 6.85 (m, 3H), 4.72 (d, J = 13.8 Hz, 1H), 
4.69 (s, 1H), 4.18 (d, J = 13.7 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 164.21 (C), 135.59 (C), 134.75 (C), 134.09 (C), 
133.21 (CH), 128.91 (CH), 128.56 (CH), 128.51 (CH), 128.03 (CH), 126.47 
(C), 124.35 (C), 120.52 (C), 120.33 (C), 115.85 (CH), 114.04 (CH), 85.57 
(C), 82.24 (C), 53.21 (CH), 51.89 (CH2). 
HRMS (ESI+): m/z 373.1102 [M + H]+, C23H18ClN2O requires 373.1096. 
4-Benzyl-3-((3-fluorophenyl)ethynyl)-3,4-dihydroquinoxalin-
2(1H)-one (3ae) 
Yield: following Procedure A, 21.8 mg (61%); following Procedure B, 21.5 
mg (60%); yellow oil. 
IR (neat): 1672, 1247, 727, 695 cm-1. 
1H NMR (300 MHz, CDCl3) δ 9.42 (bs, 1H), 7.54 – 7.22 (m, 5H), 7.20 – 6.84 
(m, 8H), 4.73 (d, J = 13.6 Hz, 1H), 4.70 (s, 1H), 4.18 (d, J = 13.6 Hz, 1H). 
19F NMR (282 MHz, CDCl3) δ -109.54. 
13C NMR (75 MHz, CDCl3) δ 164.35 (C), 162.11 (C, d, JC-F = 246.7 Hz), 135.57 
(C), 134.06 (C), 129.76 (CH, d, J = 8.6 Hz), 128.91 (CH), 128.58 (CH), 128.03 
(CH), 127.88 (CH, d, JC-F =3.2 Hz), 126.49 (C), 124.37 (CH), 123.64 (C, d, JC-
F = 9.4 Hz), 120.56 (CH), 118.77 (CH, d, JC-F = 23.0 Hz), 116.06 (CH, d, JC-F = 
21.2 Hz), 115.95 (CH), 114.01 (CH), 85.41 (C, d, JC-F = 3.3 Hz), 82.23 (C), 
53.11 (CH), 51.87 (CH2). 
HRMS (ESI+): m/z 357.1396 [M + H]+, C23H18FN2O requires 357.1398. 
4-Benzyl-3-(4-phenylbut-1-yn-1-yl)-3,4-dihydroquinoxalin-2(1H)-
one (3af) 
Yield: following Procedure A, 12.1 mg (33%); following Procedure B, 15.6 
mg (43%); yellow oil. 
IR (neat):  1685, 1504, 740, 695 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.59 (bs, 1H), 7.29 – 7.19 (m, 5H), 7.18 – 7.08 
(m, 3H), 7.03 – 6.91 (m, 3H), 6.85 – 6.75 (m, 2H), 6.73 (d, J = 8.1 Hz, 1H), 
4.47 (d, J = 13.7 Hz, 1H), 4.32 (t, J = 2.1 Hz, 1H), 3.88 (d, J = 13.7 Hz, 1H), 
2.62 (dd, J = 10.8, 4.2 Hz, 2H), 2.33 (ddd, J = 4.6, 3.4, 1.8 Hz, 2H). 
13C NMR (75 MHz, CDCl3) δ 164.68 (C), 140.25 (C), 135.81 (C), 134.27 (C), 
128.77 (CH), 128.51 (CH), 128.45 (CH), 128.33 (CH), 127.83 (CH), 126.49 
(C), 126.23 (CH), 124.17 (CH), 120.21 (CH), 115.61 (CH), 114.01 (CH), 
86.68 (C), 72.77 (C), 52.76 (C), 51.54 (CH2), 34.58 (CH2), 20.70 (CH2). 
4-Benzyl-3-(cyclopropylethynyl)-3,4-dihydroquinoxalin-2(1H)-one 
(3ag) 
Yield: following Procedure B, 9.4 mg (31%); colorless oil. 
IR (neat): 1690, 1504, 744, 701 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.58 (bs, 1H), 7.41 – 7.28 (m, 5H), 7.01 (ddd, 
J = 7.9, 6.8, 2.2 Hz, 1H), 6.92 – 6.77 (m, 3H), 4.63 (d, J = 13.8 Hz, 1H), 4.41 
(d, J = 1.8 Hz, 1H), 4.09 (d, J = 13.8 Hz, 1H), 1.19 – 1.07 (m, 1H), 0.74 – 0.64 
(m, 2H), 0.60 – 0.51 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 164.64 (C), 135.91 (C), 134.28 (C), 128.78 
(CH), 128.45 (CH), 127.83 (CH), 126.48 (C), 124.12 (CH), 120.15 (CH), 
115.55 (CH), 114.00 (CH), 90.79 (C), 66.94 (C), 52.98 (CH), 51.71 (CH2), 
8.49 (CH2), -0.55 (CH). 
HRMS (ESI+): m/z 303.1499 [M + H]+, C20H19N2O requires 303.1497. 
4-benzyl-3-((2-methoxyphenyl)ethynyl)-3,4-dihydroquinoxalin-
2(1H)-one (3ah) 
Yield: following Procedure C, 16.2 mg (44%); brown oil. 
IR (neat): 1685, 1493, 1259, 1026, 728, 700 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.72 (bs, 1H), 7.46 (dd, J = 7.9, 1.5 Hz, 2H), 
7.40 – 7.30 (m, 3H), 7.25 – 7.18 (m, 2H), 7.08 – 6.97 (m, 1H), 6.94 – 6.76 
(m, 5H), 4.71 (d, J = 14.0 Hz, 1H), 4.69 (s, 1H), 4.23 (d, J = 13.5 Hz, 1H), 3.75 
(s, 3H). 
13C NMR (75 MHz, CDCl3) δ 164.37 (C), 160.46 (C), 135.83 (C), 134.50 (C), 
133.58 (CH), 130.02 (CH), 128.82 (CH), 128.78 (CH), 127.91 (CH), 126.66 
(C), 124.13 (CH), 120.33 (CH), 120.21 (CH), 115.65 (CH), 114.17 (CH), 
111.40 (C), 110.77 (CH), 85.14 (C), 83.24 (C), 55.67 (CH3), 53.44 (CH), 
51.72 (CH2). 
HRMS (ESI+): m/z 368.1529 [M + H]+, : C24H20N2O2 requires 368.1525. 
4-Benzyl-3-(2-(4-methoxyphenyl)-2-oxoethyl)-3,4-
dihydroquinoxalin-2(1H)-one (4a) 
Yield: following Procedure A, 12.8 mg (33%);  following Procedure B, 21.6 
mg (56%); bright yellow oil. 
IR (neat): 1683, 1593, 1506, 740, 695 cm-1. 
1H NMR (300 MHz, CDCl3) δ 9.12 (bs, 1H), 7.80 (d, J = 9.0 Hz, 2H), 7.28 – 
7.21 (m, 5H), 6.86 (d, J = 8.9 Hz, 1H), 6.80 – 6.75 (m, 2H), 6.64 (d, J = 7.9 
Hz, 2H), 4.69 (dd, J = 7.5, 4.4 Hz, 1H), 4.55 (d, J = 15.6 Hz, 1H), 4.42 (d, J = 
15.6 Hz, 1H), 3.82 (s, 3H), 3.28 (dd, J = 15.7, 7.5 Hz, 1H), 3.11 (dd, J = 15.7, 
4.4 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 195.49 (C), 168.16 (C), 163.70 (C), 137.13 (C), 
133.14 (C), 130.57 (CH), 129.55 (C), 128.60 (CH), 127.31 (CH), 127.29 
(CH), 126.24 (C), 124.21 (CH), 119.38 (CH), 115.60 (CH), 114.63 (CH), 
113.76 (CH), 59.26 (CH), 55.44 (CH3), 53.57 (CH2), 38.56 (CH2). 
HRMS (ESI+): m/z 387.1697 [M + H]+, C24H23N2O3 requires 387.1703. 
4-Benzyl-3-(2-(2-methoxyphenyl)-2-oxoethyl)-3,4-
dihydroquinoxalin-2(1H)-one (4b) 
Yield: following Procedure A, 25.1 mg (65%); yellow oil. 
IR (neat): 1679, 1595, 1506, 1290, 1245, 746 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.50 (bs, 1H), 7.65 (dd, J = 7.7, 1.8 Hz, 1H), 
7.43 (ddd, J = 8.4, 7.3, 1.9 Hz, 1H), 7.29 – 7.16 (m, 5H), 7.00 – 6.94 (m, 1H), 
6.92 – 6.83 (m, 2H), 6.76 (dd, J = 5.0, 0.9 Hz, 2H), 6.62 (d, J = 7.8 Hz, 1H), 
4.70 (dd, J = 7.8, 4.3 Hz, 1H), 4.56 (d, J = 15.8 Hz, 1H), 4.41 (d, J = 15.8 Hz, 
1H), 3.73 (s, 3H), 3.41 (dd, J = 15.9, 7.9 Hz, 1H), 3.20 (dd, J = 15.9, 4.4 Hz, 
1H). 
13C NMR (75 MHz, CDCl3) δ 198.89 (C), 168.00 (C), 158.57 (C), 137.36 (C), 
133.94 (CH), 133.37 (C), 130.74 (CH), 128.56 (CH), 127.54 (C), 127.21 
(CH), 127.15 (CH), 126.30 (C), 124.05 (CH), 120.71 (CH), 119.12 (CH), 
115.31 (CH), 114.59 (CH), 111.47 (CH), 59.42 (CH), 55.34 (CH3), 53.64 
(CH2), 43.70 (CH2). 
HRMS (ESI+): m/z 387.1708 [M + H]+, C24H23N2O3 requires 387.1703. 
4-Benzyl-3-(2-oxo-2-(thiophen-2-yl)ethyl)-3,4-dihydroquinoxalin-
2(1H)-one (4c) 
Yield: following Procedure A, 19.2 mg (53%); yellow solid, m. p.: 202-208 
°C. 
IR (neat): 1681, 1599, 1234, 1305, 623 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.36 (bs, 1H), 7.88 (dd, J = 2.9, 1.3 Hz, 1H), 
7.45 (dd, J = 5.1, 1.3 Hz, 1H), 7.28 (d, J = 2.9 Hz, 1H), 7.26 – 7.18 (m, 5H), 
6.92 (ddd, J = 8.0, 6.7, 2.3 Hz, 1H), 6.88 – 6.73 (m, 2H), 6.66 (d, J = 7.9 Hz, 
1H), 4.65 (dd, J = 7.5, 4.3 Hz, 1H), 4.55 (d, J = 15.6 Hz, 1H), 4.41 (d, J = 15.6 
Hz, 1H), 3.22 (dd, J = 15.5, 7.6 Hz, 1H), 3.07 (dd, J = 15.5, 4.3 Hz, 1H). 
13C NMR (75 MHz, CDCl3) δ 191.18 (C), 167.57 (C), 141.72 (C), 136.96 (C), 
133.12 (C), 132.73 (CH), 128.65 (CH), 127.43 (CH), 127.35 (CH), 126.89 
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(CH), 126.56 (CH), 126.11 (C), 124.33 (CH), 119.52 (CH), 115.41 (CH), 
114.74 (CH), 59.14 (CH), 53.63 (CH2), 40.33 (CH2). 
HRMS (ESI+): m/z 345.1068 [M + H]+, C21H17N2OS requires 345.1062. 
(Z)-4-Benzyl-3-styryl-3,4-dihydroquinoxalin-2(1H)-one (5) 
In a 25 mL round bottomed flask was added compound 3aa (20.6 mg, 
0.061 mmol) and it was dissolved in benzene (1 mL). Then, Lindlar 
Catalyst (4 mg, 5 wt. % over CaCO3, poisoned with lead) was added and 
the resulting mixture was stirred at rt for 24 h in the presence of an 
hydrogen-filled balloon. When the starting material disappeared (as 
showed by TLC) the reaction mixture was filtered through a pad of silica 
to afford compound 5 (20.5 mg, 0.060 mmol, 99% yield). 
Yield: 20.5 mg (99%); yellow oil. 
IR (neat): 1677, 1504, 1375, 740, 697 cm-1. 
1H NMR (400 MHz, CDCl3) δ 8.98 (bs, 1H), 7.61 – 7.53 (m, 2H), 7.41 – 7.28 
(m, 4H), 7.13 – 6.92 (m, 5H), 6.89 – 6.76 (m, 3H), 6.73 (d, J = 8.0 Hz, 1H), 
5.57 (dd, J = 11.4, 10.4 Hz, 1H), 4.83 (d, J = 10.5 Hz, 1H), 4.48 (d, J = 14.3 
Hz, 1H), 3.80 (d, J = 14.3 Hz, 1H). 
13C NMR (101 MHz, CDCl3) δ 167.74 (C), 136.00 (C), 135.56 (CH), 133.97 
(C), 128.94 (CH), 128.31 (CH), 127.88 (CH), 127.78 (CH), 127.16 (CH), 
126.11 (C), 124.18 (CH), 122.63 (CH), 119.28 (CH), 115.48 (CH), 113.26 
(CH), 58.23 (CH), 51.32 (CH2). 
HRMS (ESI+): m/z 341.1647 [M + H]+, C23H21N2O requires 341.1648. 
4-Benzyl-3-phenethyl-3,4-dihydroquinoxalin-2(1H)-one (6) 
In a 25 mL round bottomed flask was added compound 3aa (19.4 mg, 
0,057 mmol) and it was dissolved in EtOH (5 mL). Then, Pd 5% over CaCO3 
(7.4 mg, 0.003 mmol) was added and the resulting mixture was stirred at 
rt for 5 h in the presence of an hydrogen-filled balloon. When the starting 
material disappeared (as showed by TLC) the reaction mixture was 
filtered through a pad of silica to afford compound 6 (19.4 mg, 0.057 
mmol, 99% yield). 
Yield: 19.4 mg (99%); yellow oil. 
IR (neat): 1672, 1495, 742, 697 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.64 (bs, 1H), 7.35 – 7.20 (m, 7H), 7.20 – 7.08 
(m, 3H), 6.98 – 6.88 (m, 1H), 6.81 – 6.76 (m, 2H), 6.72 (d, J = 7.9 Hz, 1H), 
4.63 (d, J = 15.0 Hz, 1H), 4.21 (d, J = 15.0 Hz, 1H), 3.97 – 3.84 (m, 1H), 2.78 
– 2.56 (m, 2H), 2.02 – 1.81 (m, 2H). 
13C NMR (75 MHz, CDCl3) δ 168.17 (C), 141.03 (C), 136.69 (C), 134.05 (C), 
128.74 (CH), 128.38 (CH), 128.34 (CH), 127.68 (CH), 127.56 (CH), 126.27 
(C), 126.00 (CH), 124.15 (CH), 119.27 (CH), 115.33 (CH), 113.99 (CH), 
61.25 (CH), 53.12 (CH2), 31.67 (CH2), 30.73 (CH2). 
HRMS (ESI+): m/z 343.1804 [M + H]+, C23H23N2O requires 343.1805. 
3-Phenethyl-3,4-dihydroquinoxalin-2(1H)-one (7) 
In a 25 mL round bottomed flask was added compound 3aa (22.4 mg, 
0,066 mmol) and it was dissolved in EtOH (6 mL). Then, Pd 10% over C 
(8.6 mg, 0.008 mmol) was added and the resulting mixture was stirred at 
rt for 2.5 h in the presence of an hydrogen-filled balloon. When the 
starting material disappeared (as showed by TLC) the reaction mixture 
was filtered through a pad of silica to afford compound 7 (15.8 mg, 0.063 
mmol, 95% yield). 
Yield: 15.8 mg (95%); brown solid, m. p.: 195-200 °C. 
IR (neat): 3058, 3027, 1664, 1603, 1504, 1370, 1303, 740, 695 cm-1. 
1H NMR (300 MHz, CDCl3) δ 8.65 (bs, 1H), 7.34 – 7.27 (m, 2H), 7.25 – 7.17 
(m, 3H), 6.88 (ddd, J = 7.8, 6.2, 2.7 Hz, 1H), 6.82 – 6.67 (m, 2H), 6.56 (d, J = 
7.6 Hz, 1H), 3.96 (ddd, J = 7.6, 4.6, 2.1 Hz, 1H), 3.80 (bs, 1H), 2.81 (td, J = 
9.2, 4.6 Hz, 2H), 2.32 – 2.14 (m, 1H), 2.05 (ddd, J = 15.9, 14.4, 7.4 Hz, 1H). 
 13C NMR (75 MHz, CDCl3) δ 168.71 (C), 140.93 (C), 132.83 (C), 128.61 
(CH), 128.41 (CH), 126.22 (CH), 125.24 (C), 123.85 (CH), 119.44 (CH), 
115.30 (CH), 114.21 (CH), 56.13 (CH), 33.25 (CH2), 31.88 (CH2). 
HRMS (ESI+): m/z 253.1334 [M + H]+, C16H17N2O requires 253.1335. 
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